[metaslider id=19676]
Day One kicked-off with numerous informational sessions, including talks on the role of AI in clinical decision-making, the importance of standardization for reimbursement, and the tremendous potential of genomic profiling in disease prevention, diagnosis, and treatment.
Dan Richards, Vice President of Biomedical Informatics at QIAGEN, spoke about the clinician's current challenge of curating all the evidence he or she needs to confidently sign-off on variant reports before they go to the prescribing physician. QIAGEN Clinical Insight (QCI) and N-of-One were featured as solutions providing options for either in-house curation with tailored workflows or on-demand curation services.
On Tuesday morning, the conversation continued with a panel hosted by Sean Scott, Chief Business Officer of Clinical Genomics and Bioinformatics at QIAGEN, that discussed the emergence and application of real-world evidence in the clinical setting, especially in precision diagnostics and clinical trial protocol design.
The panel consisted of Raju K Pillai, MD, Hematopathologist and Molecular Pathologist at City of Hope National Medical Center, James Hadfield, Director and Principal Diagnostic Scientist at AstraZeneca, and Sheryl Krevsky Elkin, Chief Scientific Officer of N-of-One.
Also on Tuesday morning, Mary Napier, Associate Director of NGS Strategy at QIAGEN, gave a timely talk on how diagnostic labs and pharma companies can gain a comprehensive understanding of tumor mutational burden signature by implementing our new QIAseq Tumor Mutational Burden panel.
What does she mean by "comprehensive"?
Find out here!
Thank you to everyone who visited the QIAGEN booth, we truly enjoyed talking to all of you about the industry challenges, and changes you see happening now and in the future.
See you at our next event:
Advances in Genome Biology and Technology (AGBT) 2019 in Marco Island, Florida!
February 27th - March 2nd
Want to know more about our clinical solutions and real-world evidence?
We were honored to take part in last month’s Personalized Medicine World Conference (PMWC), where speakers and attendees focused on critical areas such as liquid biopsies, pathology, immuno-oncology, next-generation sequencing, and more.
Sean Scott, VP, New Ventures here at QIAGEN Bioinformatics, presented a talk on “Enabling precision medicine in oncology through scalable NGS-based test interpretation and actionable reporting.” Sean has presented at the PWMC event for the past four years and this event continues to grow in importance. If you couldn’t make it to the event, here’s a quick recap of his presentation.
Sean reviewed current trends and shifts in NGS-based testing of cancer patients, noting the significant improvement in our ability to treat this disease by using genomic information. He walked through some of the challenges facing clinical testing labs, such as scientific and technical complexity of NGS tests, the operational scale challenges with NGS tests, the opportunity for labs to differentiate their test offerings through bioinformatics and data aggregation, as well as continued uncertainty in reimbursement hurdles.
Sean showcased the value of the QIAGEN Clinical Insight platform in enabling clinical labs in scaling their test analysis, interpretation and reporting in both somatic and inherited/germline cancers. He also presented on QIAGEN’s strategy for de-identified genomic data and progress with the Allele Frequency Community, an opt-in community co-founded by QIAGEN Bioinformatics that allows labs to share allele frequency statistics for the benefit of patients and clinical research, and the INOVA Compendium.
As always, the PMWC event was an excellent event. If you couldn’t make it this year, we hope to see you there next year!
Learn more about QIAGEN Clinical Insight
